Clinical effects of human macrophage inflammatory protein-1 alpha MIP- 1α (LD78) administration to humans: A phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1023-1029

  Marshall, E ^a   Howell, A H ^a   Powles, R ^b   Hunter, M G ^c   Edwards, M ^c   Wood, L M ^c   Czaplewski, L ^c   Puttick, R ^c   Warrington, S ^d   Boyce, M ^d   Testa, N ^e   Dexter, T M ^e   Lord, B I ^e   Millar, A ^d  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c British Biotech Pharmaceuticals Ltd   (United Kingdom)

^d CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BB 10010; LD78; MIP 1 ; Mobilisation; Phase I study; Stem cell

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; GENETIC ENGINEERING; HEMATOPOIESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; PRIORITY JOURNAL; STEADY STATE; STEM CELL;

ADULT; AGED; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS; LEUKOCYTE COUNT; LEUKOCYTES; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED;

EID: 20244382086     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10141-1     Document Type: Article

References (21)

1. Wolpe SD, Davatelis SG, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988, 167, 570-581.
2. Wolpe S. D., Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J. 3:1989;2565-2573.
3. Clements JM, Craig S, Gearing AJH, et al. Biological and structural properties of MIP-1α expressed in yeast. Cytokine 1992, 4, 76-82.
4. Lord BI, Dexter TM, Clements JM, et al. Macrophage inflammatory protein protects multipotent haemopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 1992, 79, 2605-2609.
5. Dunlop DJ, Wright EG, Lorimore S, et al. Demonstration of stem cell inhibition and myeloproliferative effects of SCI/rhMIP1α in vivo. Blood 1992, 9, 2221-2225.
6. Lord BI, Woolford LB, Wood LM, et al. Mobilisation of early haematopoietic progenitor cells with BB10010: a genetically engineered variant of human macrophage inflammatory protein-1α. Blood 1995, 85, 3412-3415.
7. Canque B, Gluckmann A. MIP-1α is induced by and it inhibits HIV infection of blood derived macrophages. Blood 1994, 84, 10(Suppl. 1), 480 (abstract 1907).
8. + T cells. Science 1995, 270, 1811.
9. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381, 667.
10. Hunter MG, Bawden L, Brotherton D, et al. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood 1995, 12, 4406-4408.
11. Lord BI, Marshall E, Woolford LB, et al. BB-10010/MIP-1α in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer 1996, 74, 1017-1022.
12. McCourt M, Brotherton D, Comer M, et al. BB-10010, a variant of the human stem cell inhibitor LD78, produces a rapid increase in both mature white blood cells and circulating haemopoietic progenitors. Bone Marrow Transplant 1994, 14(Suppl. 2), S34 .
13. Couthino LH, Gilleece MH, Wynter EA de, et al. Clonal and long term cultures using human bone marrow. In Testa NG, Molineux G, eds. Haemopoiesis: A Practical Approach. Oxford, Oxford University Press, 1993, 75.
14. Siena S, Bregni M, Di Nicola M, et al. Milan protocol for clinical CD34 cell estimation in peripheral blood for autografting in patients with cancer. In Wunder E, Sovalat H, Henon PR, Serke S, eds. Haemopoietic Stem Cells. The Mulhouse Manual. Alpha Med Press, 1994, 23.
15. Davatelis G, Wolpe SD, Sherry B, et al. Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science 1989, 243, 1066-1068.
16. Myers RD, Paez X, Roscoe AK, et al. Fever and feeding: differential actions of macrophage inflammatory protein-1(MIP-1), MIP-1alpha and MIP-1beta on rat hypothalamus. Neurochem Res 1993, 18, 667.
17. Meurer R, Van Riper G, Feeney W, et al. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein-1, human macrophage inflammatory protein-1alpha or human interleukin-8. J Exp Med 1993, 178, 1913.
18. Appelberg R. Interferon gamma (IFN-γ) and macrophage inflammatory proteins (MIP)-1 and 2 are involved in the regulation of the T-cell dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Clin Exp Immunol. 89:1992;269.
19. McColl SR, Hachicha M, Levasseur S, et al. Uncoupling of early signal transduction events from effector function in human peripheral blood neutrophils in response to recombinant macrophage inflammatory protein-1α and -1β. J Immunol 1993, 150, 4550-4560.
20. Kasama T, Strieter RM, Standiford TJ, et al. Expression and regulation of human neutrophil-derived macrophage inflammatory protein-1alpha. J Exp Med 1993, 178, 63.
21. Steward WP, Scarffe JH, Austin R, et al. Recombinant human granulocyte macrophage colony stimulating factor (rh GM-CSF) given as daily short infusions - a phase I dose-toxicity study. Br J Cancer 1989, 59, 142.